Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2010-12-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2010.135525PMID 21173016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome.

  2010cited by this paper
• Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.

  2009cited by this paper
• Statins for the Treatment of Antiphospholipid Syndrome?

  2009cited by this paper
• Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome

  2009cited by this paper
• Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis.

  2008cited by this paper
• Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.

  2008cited by this paper
• In Vivo Effects of an Inhibitor of Nuclear Factor‐Kappa B on Thrombogenic Properties of Antiphospholipid Antibodies

  2007cited by this paper
• Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.

  2007cited by this paper
• Involvement of annexin A2 in anti-beta2GPI/beta2GPI-induced tissue factor expression on monocytes.

  2007cited by this paper
• Disulfide isomerization switches tissue factor from coagulation to cell signaling

  2006cited by this paper
• Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved.

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

  2006cited by this paper
• Emerging insights in tissue factor-dependent signaling events.

  2006cited by this paper
• Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.

  2006cited by this paper
• Rho and vascular disease.

  2005cited by this paper
• More on: fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

  2005cited by this paper
• Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway*

  2005cited by this paper
• Tissue factor mediates inflammation.

  2005cited by this paper
• Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies.

  2005cited by this paper
• Regulation of angiogenesis by tissue factor cytoplasmic domain signaling

  2004cited by this paper
• The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies.

  2004cited by this paper
• Protein disulfide isomerase suppresses the transcriptional activity of NF-κB

  2004cited by this paper
• Role of thrombin in angiogenesis and tumor progression.

  2004cited by this paper
• Protein disulfide isomerase suppresses the transcriptional activity of NF-kappaB.

  2004cited by this paper
• Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

  2004cited by this paper
• Tissue factor-factor VIIa signaling.

  2004cited by this paper
• HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells.

  2003cited by this paper
• Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF‐1α

  2003cited by this paper
• Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects

  2003cited by this paper
• 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA

  2002cited by this paper
• Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin1

  2001cited by this paper
• Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.

  2001cited by this paper
• Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells.

  2000cited by this paper
• Increased Levels of Tissue Factor mRNA in Mononuclear Blood Cells of Patients with Primary Antiphospholipid Syndrome

  1999cited by this paper
• Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1.

  1998cited by this paper
• Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression.

  1997cited by this paper
• Criteria for the Diagnosis of Lupus Anticoagulants: An Update

  1995cited by this paper
• A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

  1991cited by this paper

• Simvastatin Restores Uteroplacental Hemodynamics and Trophoblast Function in Obstetric Antiphospholipid Syndrome in a Placenta-on-a-Chip Model.

  2026cites this paper
• Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting.

  2026cites this paper
• Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications

  2025cites this paper
• Simvastatin competitively inhibits cellular signalling of lipid-binding antiphospholipid antibodies.

  2025cites this paper
• Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome

  2025cites this paper
• The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature

  2024cites this paper
• Obstetric antiphospholipid syndrome carries an increased lifetime risk for obstetric and thrombotic complications—a population-based study

  2024cites this paper
• Intima media thickness of the carotid artery in primary antiphospholipid syndrome: A systematic review and meta-analysis.

  2024cites this paper
• Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts

  2023cites this paper
• How to diagnose and manage antiphospholipid syndrome.

  2023cites this paper
• Role of Lipid Rafts on LRP8 Signaling Triggered by Anti-β2-GPI Antibodies in Endothelial Cells

  2023cites this paper
• Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach

  2023cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cites this paper
• What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?

  2022cites this paper
• Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis.

  2022cites this paper
• Old and new damage‐associated molecular patterns (DAMPs) in autoimmune diseases

  2022cites this paper
• Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review.

  2021cites this paper
• Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome.

  2021cites this paper
• Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome

  2021cites this paper
• Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations

  2021cites this paper
• Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots

  2021cites this paper
• Association between statin use and incidence of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center retrospective cohort study

  2020cites this paper
• Thrombophilia

  2020cites this paper
• Statins and autoimmunity: State-of-the-art.

  2020cites this paper
• Proteins Involved in the Induction of Procoagulant Activity and Autoimmune Response in Patients With Primary Antiphospholipid Syndrome

  2020cites this paper
• Antiphospholipid syndrome: a clinical perspective

  2020influential citation
• Treatment of thrombotic antiphospholipid syndrome in adults and children.

  2020cites this paper
• Pathogenesis of Antiphospholipid Antibody Syndrome

  2019cites this paper
• Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus

  2019cites this paper
• Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome

  2019cites this paper
• Is there a role for immunosuppression in antiphospholipid syndrome?

  2019cites this paper
• Antiphospholipid syndrome.

  2019cites this paper
• Pulmonary involvement in antiphospholipid syndrome

  2019cites this paper
• 9th Annual Meeting of the Lupus Academy Meeting Report

  2019cites this paper
• Treatment of antiphospholipid syndrome beyond anticoagulation.

  2019cites this paper
• Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

  2018cites this paper
• Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies

  2018influential citation
• The treatment of anti-phospholipid syndrome: A comprehensive clinical approach.

  2018cites this paper
• Management of antiphospholipid syndrome

  2018influential citation
• New and upcoming treatments in antiphospholipid syndrome: A comprehensive review

  2018cites this paper
• THE ADVANTAGES AND DISADVANTAGES OF STATIN THERAPY FOR DYSLIPIDEMIA

  2018cites this paper
• Clinical profiles and risk assessment in patients with antiphospholipid antibodies

  2018cites this paper
• Diagnosis and Management of the Antiphospholipid Syndrome

  2018cites this paper
• Neutrophil Extracellular Traps, Antiphospholipid Antibodies and Treatment

  2017cites this paper
• Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins.

  2017cites this paper
• Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies.

  2017cites this paper
• Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial

  2017cites this paper
• Statins: pros and cons.

  2017cites this paper
• New Insights in the Pathophysiology of Antiphospholipid Syndrome

  2017cites this paper
• Mechanisms of atherosclerosis and cardiovascular disease in antiphospholipid syndrome and systemic lupus erythematosus. New therapeutic approaches.

  2017cites this paper
• Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies

  2017cites this paper
• 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report

  2017cites this paper
• Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis

  2017cites this paper
• eview tatins : pros and cons ago

  2017cites this paper
• Mecanismos de aterosclerosis y enfermedad cardiovascular en el síndrome antifosfolípido y el lupus eritematoso sistémico. Alternativas terapéuticas

  2017cites this paper
• Antiphospholipid Syndrome

  2017cites this paper
• Emerging Therapies in Antiphospholipid Syndrome

  2016cites this paper
• The role of invariant Natural Killer T cells in SLE patients with atherosclerosis

  2016cites this paper
• Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment.

  2016cites this paper
• Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?

  2016cites this paper
• Análisis de los mecanimos celulares y moleculares reguladores del efecto de la Fluvastatina y nuevos fármacos antioxidantes en la prevención de la trombosis y la aeterotrombosis asociadas al Síndrome Antifosfolipido y al Lupus Eritematoso Sistémico. Estudio Genómico y Proteómico

  2016cites this paper
• Delineating the deranged immune system in the antiphospholipid syndrome.

  2016cites this paper
• Antiphospholipid syndrome: an update

  2015cites this paper
• Immunotherapy in antiphospholipid syndrome.

  2015cites this paper
• Antiphospholipid Antibody Carriers

  2015cites this paper
• Antiphospholipid Syndrome (APS) - An Update on Clinical Features and Treatment Options

  2015cites this paper
• Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches

  2015cites this paper
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• C URRENT OPINION Targeted therapy in antiphospholipid syndrome

  2014cites this paper
• Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

  2014cites this paper
• Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence

  2014cites this paper
• Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment

  2014cites this paper
• The future of treatment for antiphospholipid syndrome

  2014cites this paper
• Targeted therapy in antiphospholipid syndrome

  2014cites this paper
• Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort.

  2014cites this paper
• Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety

  2014cites this paper
• Antiphospholipid Syndrome Novel Therapies

  2014cites this paper
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

  2014influential citation
• Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics.

  2014cites this paper
• 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

  2014cites this paper
• Statins and autoimmunity

  2013cites this paper
• Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome

  2013cites this paper
• Statins and autoimmunity

  2013cites this paper
• Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies.

  2013cites this paper
• A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients

  2013cites this paper
• [New alternatives for the treatment of antiphospholipid syndrome. A literature review].

  2013cites this paper
• Clinical Aspects of the Antiphospholipid Syndrome

  2013cites this paper
• 6 – Que faire en présence d'anticorps antiphospholipides chez un malade lupique sans passé thrombotique ni obstétrical ?

  2013cites this paper
• Treatment of the antiphospholipid syndrome

  2013cites this paper
• Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

  2012cites this paper
• The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

  2012cites this paper
• Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review.

  2012cites this paper
• Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'.

  2012cites this paper
• Potential Use of Statins in the Treatment of Antiphospholipid Syndrome

  2012cites this paper
• To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer.

  2012cites this paper